Effective continuous systemic therapy of severe plaque-type psoriasis is accompanied by amelioration of biomarkers of cardiovascular risk: Results of a prospective longitudinal observational study

Journal of the European Academy of Dermatology and Venereology

Volumn 25, Issue 10, 2011, Pages 1187-1193

  Boehncke, S ^a   Salgo, R ^b   Garbaraviciene, J ^b   Beschmann, H ^b   Hardt, K ^b   Diehl, S ^b   Fichtlscherer, S ^c   Thaci D ^b   Boehncke, W H ^b  

^a Department of Internal Medicine   (Germany)

^b GOETHE UNIVERSITY   (Germany)

^c UNIVERSITY HOSPITAL FRANKFURT   (Germany)

Author keywords

biomarkers; comorbidity; insulin resistance; mortality; psoriasis; therapy

Indexed keywords

ADALIMUMAB; ADIPOCYTOKINE; ADIPONECTIN; ANTIPSORIASIS AGENT; C PEPTIDE; C REACTIVE PROTEIN; CYCLOSPORIN A; ETANERCEPT; FUMARIC ACID DERIVATIVE; GLUCOSE; INSULIN; LEPTIN; METHOTREXATE; RESISTIN; TUMOR NECROSIS FACTOR ALPHA; USTEKINUMAB; VASCULOTROPIN;

ABSENCE OF SIDE EFFECTS; ADULT; AGED; ARTICLE; CARDIOVASCULAR RISK; CLINICAL ARTICLE; CONTINUOUS SYSTEMIC THERAPY; DISEASE COURSE; DISEASE SEVERITY; FEMALE; GLUCOSE BLOOD LEVEL; HEART PROTECTION; HOMEOSTASIS MODEL ASSESSMENT; HUMAN; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; LEUKOCYTE COUNT; LONGITUDINAL STUDY; MALE; OBSERVATIONAL STUDY; ORAL GLUCOSE TOLERANCE TEST; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; PSORIASIS AREA AND SEVERITY INDEX; PSORIASIS VULGARIS; PSORIATIC INFLAMMATION; RATING SCALE; SKIN INFLAMMATION; SYSTEMIC THERAPY; TREATMENT OUTCOME;

ADIPOKINES; ADULT; AGED; ANTIBODIES, MONOCLONAL, HUMANIZED; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; CARDIOVASCULAR DISEASES; CYCLOSPORINE; FEMALE; FUMARATES; HUMANS; IMMUNOGLOBULIN G; LONGITUDINAL STUDIES; MALE; METHOTREXATE; MIDDLE AGED; PROSPECTIVE STUDIES; PSORIASIS; RECEPTORS, TUMOR NECROSIS FACTOR; RESISTIN; RISK FACTORS; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 79957605293     PISSN: 09269959     EISSN: 14683083     Source Type: Journal    
DOI: 10.1111/j.1468-3083.2010.03947.x     Document Type: Article

References (33)

1. Smith CH, Barker JNWN,. Psoriasis and its management. BMJ 2006; 333: 380-384.
2. Nestle FO, Kaplan DH, Barker JNWN,. Psoriasis. N Engl J Med 2009; 361: 496-509.
3. Boehncke W-H, Boehncke S, Schön MP,. Managing comorbid disease in patients with psoriasis. BMJ 2010; 340: b5666.doi: 10.1136/bmj.b5666
4. Gelfand JM, Neimann AL, Shin DB, Wang X, Margolis DJ, Troxel AB,. Risk of myocardial infarction in patients with psoriasis. JAMA 2006; 296: 1735-1741.
5. Ludwig RJ, Herzog C, Rostock A, et al. Psoriasis: a possible risk factor for development of coronary artery calcification. Br J Dermatol 2007; 156: 271-276.
6. Gelfand JM, Troxel AB, Lewis JD, et al. The risk of mortality in patients with psoriasis: results from a population-based study. Arch Dermatol 2007; 143: 1493-1499.
7. Stern RS,. Psoriasis is not a useful independent risk factor for cardiovascular disease. J Invest Dermatol 2010; 130: 917-919.
8. Hansson GK,. Inflammation, atherosclerosis and coronary artery disease. N Engl J Med 2005; 352: 1685-1695.
9. Boehncke S, Thaci D, Beschmann H, et al. Psoriasis patients show signs of insulin resistance. Br J Dermatol 2007; 157: 1249-1251.
10. Jansson PA,. Endothelial dysfunction in insulin resistance and type 2 diabetes. J Int Med 2007; 262: 173-183.
11. Kearney MT, Duncan ER, Kahn M, Wheatcroft SB,. Insulin resistance and endothelial cell dysfunction: studies in mammalian models. Exp Physiol 2008; 93: 158-163.
12. Nast A, Kopp I, Augustin M, et al. German evidence-based guidelines for the treatment of psoriasis vulgaris (short version). Arch Dermatol Res 2007; 299: 111-138.
13. Finlay AY,. Current severe psoriasis and the rule of tens. Br J Dermatol 2005; 152: 861-867.
14. Berth-Jones J, Grotzinger K, Rainville C, et al. A study examining inter- and intrarater reliability of three scales for measuring severity of psoriasis: Psoriasis Area and Severity Index, Physician's Global Assessment and Lattice System Physician's Global Assessment. Br J Dermatol 2006; 155: 707-713.
15. Reich K, Mrowitz U,. Treatment goals in psoriasis. J Dtsch Dermatol Ges 2007; 5: 566-574.
16. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC,. Homeostasis model assessment: insulin resistance and ß-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985; 28: 412-419.
17. Walsh K,. Adipokines, myokines and cardiovascular disease. Circ J 2009; 73: 13-18.
18. Melander O, Newton-Cheh C, Almgren P, et al. Novel and conventional biomarkers for prediction of incident cardiovascular events in the community. JAMA 2009; 302: 49-57.
19. Soeki T, Tamura Y, Shinohara H, Tanaka H, Bando K, Fukuda N,. Serial changes in serum VEGF and HGF in patients with acute myocardial infarction. Cardiology 2000; 93: 168-174.
20. Steppan CM, Bayley ST, Bhat S, et al. The hormone resistin links obesity to diabetes. Nature 2001; 409: 307-312.
21. Weikert C, Westphal S, Berger K, et al. Plasma resistin levels and risk of myocardial infarction and ischemic stroke. J Clin Endocrinol Metab 2008; 93: 2647-2653.
22. Mehta NN, McGillicudy FC, Anderson PD, et al. Experimental endotoxemia induced adipose inflammation and insulin resistance in humans. Diabetes 2010; 59: 172-181.
23. Qasim A, Mehta NN, Tadesse MG, et al. Adipokines, insulin resistance and coronary artery calcification. J Am Coll Cardiol 2008; 52: 231-236.
24. Dixon WG, Watson KD, Lunt M, Hyrich KL, The British Society for Rheumatology Biologics Register Control Centre Consortium. Reduction in the incidence of myocardial infarction in patients with rheumatoid arthritis who respond to anti-tumor necrosis factor alpha therapy: results from the British Society for Rheumatology Biologics Register. Arthritis Rheum 2007; 56: 2905-2912.
25. Jacobsson LT, Turesson C, Nilsson JA, et al. Treatment with TNF blockers and mortality risk in patients with rheumatoid arthritis. Ann Rheum Dis 2007; 66: 670-675.
26. Prodanovich S, Ma F, Taylor JR, Pezon C, Fasihi T, Kirsner RS,. Methotrexate reduces incidence of vascular diseases in veterans with psoriasis or rheumatoid arthritis. J Am Acad Dermatol 2005; 52: 262-267.
27. Strober B, Teller C, Yamauchi P, et al. Effects of etanercept on C-reactive protein levels in psoriasis and psoriatic arthritis. Br J Dermatol 2008; 159: 322-330.
28. Cerman AA, Bozkrut S, Sav A, Tulunay A, Elbasi MO, Ergun T,. Serum leptin levels, skin leptin and leptin receptor expression in psoriasis. Br J Dermatol 2008; 159: 820-826.
29. Coimbra S, Oliveira H, Reis F, et al. Circulating adipokine levels in Portugese patients with psoriasis vulgaris according to body mass index, severity and therapy. J Eur Acad Dermatol Venerol 2010; 24: 1386-1394.
30. Coimbra S, Oliveira H, Reis F, et al. C-reactive protein and leucocyte activation in psoriasis vulgaris according to severity and therapy. J Eur Acad Dermatol Venerol 2010; 24: 789-796.
31. Coimbra S, Oliveira H, Reis F, et al. Psoriasis therapy and cardiovascular risk factors: a 12-week follow-up study. Am J Clin Dermatol 2010; 11: 423-432.
32. Coimbra S, Oliveira H, Reis F, et al. IL-22, IL-17, IL-23, VEGF, TNF-alpha and IL-8 levels inpsoriatic patients-before, during and after PUVA and NBUVB therapy. Br J Dermatol 2010; 63: 1282-1290.
33. Kimball AB, Gladman D, Gelfand JM, et al. National Psoriasis Foundation clinical consensus on psoriasis comorbidities and recommendations for screening. J Am Acad Dermatol 2008; 58: 1031-1042.